Combining GLP-1 Drugs With Other Diabetes Medications: What Works Best

Incretin-based drugs (GLP-1 agonists, DPP-4 inhibitors) combine effectively with metformin, sulfonylureas, and insulin for type 2 diabetes, with optimal pairing depending on patient characteristics and treatment goals.

Over, Rebecca K et al.·Current diabetes reports·2008·Moderate EvidenceReview
RPEP-01395ReviewModerate Evidence2008RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

GLP-1 agonists and DPP-4 inhibitors combine synergistically with metformin (first-line), sulfonylureas, thiazolidinediones, and insulin for T2DM, with combination selection guided by patient weight, hypo risk, and HbA1c target — practical combination pharmacotherapy guidance.

Key Numbers

How They Did This

review study.

Why This Research Matters

Relevant for glp-1, diabetes.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding GLP-1 agonists and DPP-4 inhibitors combine synergistically with metformin (first-line), sulfonylureas, thiazolidinediones, and insulin for T2DM, with
Evidence Grade:
moderate evidence.
Study Age:
Published in 2008.
Original Title:
Combination pharmacotherapy with incretins: what works best and when?
Published In:
Current diabetes reports, 8(5), 361-7 (2008)
Database ID:
RPEP-01395

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Combining GLP-1 Drugs With Other Diabetes Medications: What Works Best

What was found?

Incretin-based drugs (GLP-1 agonists, DPP-4 inhibitors) combine effectively with metformin, sulfonylureas, and insulin for type 2 diabetes, with optimal pairing depending on patient characteristics and treatment goals.

Read More on RethinkPeptides

Cite This Study

RPEP-01395·https://rethinkpeptides.com/research/RPEP-01395

APA

Over, Rebecca K; Ratner, Robert E. (2008). Combination pharmacotherapy with incretins: what works best and when?. Current diabetes reports, 8(5), 361-7.

MLA

Over, Rebecca K, et al. "Combination pharmacotherapy with incretins: what works best and when?." Current diabetes reports, 2008.

RethinkPeptides

RethinkPeptides Research Database. "Combination pharmacotherapy with incretins: what works best ..." RPEP-01395. Retrieved from https://rethinkpeptides.com/research/over-2008-combination-pharmacotherapy-with-incretins

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.